InsiderTrades

Form 4 for TYRA Tyra Biosciences, Inc.

Accepted 2021-09-17 00:00:00 ET · period of report 2021-09-17 · accession 0001104659-21-116944 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2021-09-17 2021-09-17 TYRA RA Capital Nexus Fund, L.P. Dir, 10% C - Cnv Deriv — +5.99M 4.05M New —
DI 2021-09-17 2021-09-17 TYRA RA Capital Nexus Fund, L.P. Dir, 10% P - Purchase $16.00 +1.25M 5.30M +31% +$20.00M
DMI 2021-09-17 2021-09-17 TYRA RA Capital Nexus Fund, L.P. Dir, 10% C - Cnv Deriv $0.00 -2.30M 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-09-17 C A 442,721 — 442,721 I See footnotes — — (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F5) These securities are held directly by the Account.
2 Common Common Stock 2021-09-17 C A 1,496,613 — 1,496,613 I See footnotes — — (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F3) These securities are held directly by RA Capital Nexus Fund, L.P. (the "Nexus Fund").
3 Common Common Stock 2021-09-17 P A 1,250,000 $16.00 5,297,120 I See footnotes — — (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
4 Common Common Stock 2021-09-17 C A 4,047,120 — 4,047,120 I See footnotes — — (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
5 Derivative Series B Preferred Stock 2021-09-17 C D 182,257 $0.00 0 I See footnotes — · — to — 473,394 Common Stock (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F3) These securities are held directly by RA Capital Nexus Fund, L.P. (the "Nexus Fund"). (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
6 Derivative Series B Preferred Stock 2021-09-17 C D 546,773 $0.00 0 I See footnotes — · — to — 1,420,188 Common Stock (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
7 Derivative Series A Preferred Stock 2021-09-17 C D 1,011,370 $0.00 0 I See footnotes — · — to — 2,626,932 Common Stock (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
8 Derivative Series A Preferred Stock 2021-09-17 C D 393,940 $0.00 0 I See footnotes — · — to — 1,023,219 Common Stock (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F3) These securities are held directly by RA Capital Nexus Fund, L.P. (the "Nexus Fund"). (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
9 Derivative Series A Preferred Stock 2021-09-17 C D 170,448 $0.00 0 I See footnotes — · — to — 442,721 Common Stock (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund, and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F5) These securities are held directly by the Account. (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.